2023 New Treatment Grant Recipients
The New Treatment Grants fund projects at any stage (preclinical to clinical) that will significantly accelerate treatments to pancreatic cancer patients,
and grow capacity in pancreatic cancer research in Australia. Grant applications were assessed by our international Scientific Advisory Panel comprised of international and national experts in the field.
The New Treatment Grants fund projects at any stage (preclinical to clinical) that will significantly accelerate treatments to pancreatic cancer patients and grow capacity in pancreatic cancer research in Australia. Grant applications were assessed by our international Scientific Advisory Panel comprised of international and national experts in the field.
Accelerator Grants
Receptor-directed precision medicines for pancreatic cancer.
PemOla: A phase II study combining pembrolizumab and olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
Targeting oncogenic Pol-II transcription cycles using cyclin-dependent-kinase inhibitors: a new therapeutic approach for pancreatic cancer.
Targeting lymph-pancreas interactions to treat pancreatic cancer.
New pancreatic cancer treatment involving Aryl Hydrocarbon Receptor (AhR) inhibition in the tumour and microenvironment
Polymer mimics of the TRAIL protein for pancreatic cancer
